MLTX
NASDAQ HealthcareMoonLake Immunotherapeutics - Class A Ordinary Shares
Biotechnology
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
๐ Market Data
| Price | $19.01 |
|---|---|
| Volume | 1,420,485 |
| Market Cap | 1.59B |
| Beta | 1.040 |
| RSI (14-Day) | 40.4 |
| 200-Day MA | $15.59 |
| 50-Day MA | $18.73 |
| 52-Week High | $62.75 |
| 52-Week Low | $5.95 |
| Forward P/E | -5.54 |
| Price / Book | 5.40 |
๐ฏ Investment Strategy Scores
MLTX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (71/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ Over-Hyped (20/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find MLTX in your text
Paste any article, transcript, or post โ the tool will extract MLTX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.